The myelodysplastic syndromes: Towards a functional classification

Blood Reviews

Volumn 12, Issue 2, 1998, Pages 73-83

  Mijovic A ^a   Mufti, G J ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CHEMICAL MUTAGEN; DNA TOPOISOMERASE INHIBITOR;

CLASSIFICATION; CLINICAL FEATURE; HUMAN; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW;

EID: 0031843768     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(98)90018-2     Document Type: Article

References (84)

1. Bennett JM, Catovsky D, Daniel MT et al. The French-Atnerican-British cooperative group. Proposals for the classification of myelodysplastic syndromes. Br J Haematol 1982:51: 189-199.
2. First MIC Cooperative study group. Morphologic, Immunologie and Cytogenetic (MIC) working classification of acute lymphoblastic leukemia. Cancer Genet Cytogenet 1986; 23: 189-197.
3. Second MIC Cooperative study group. Morphologic. Immunologie and Cytogenetic (MIC) working classification of acute myeloid leukemia. Cancer Genet Cytogenet 1988: 30: 1-5.
4. Harris NL. Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994;84: 1361-1392.
5. Pagliuca A, Mufti GJ. Clinicomorphological features of myelodysplastic syndromes. In: Mufti GJ, Gallon DAG. The myelodysplastic syndromes. Edinburgh Churchill Livingstone 1992: 1-14.
6. Mufti GJ. Primary myelodysplastic syndrome: prognostic value of FAB classification, scoring systems, bone marrow histology and karyotypic analysis. In: Mufti GJ, Gallon DAG. The myelodysplastic syndromes. Edinburgh Churchill Livingstone 1992: 207-224.
7. Bjorkman SE. Chronic refractory anemia with sideroblastic bone marrow. A study of four cases. Blood 1956; 11: 250-259.
8. Gatterman N, Aul C, Schneider W. Two types of acquired sideroblastic anaemia (AISA). Br J Haematol 1990; 74: 45-52.
9. Cazzola M, Barosi G, Berzuini C et al. Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes. Br J Haematol 1982; 50: 55-62.
10. Aoki Y. Multiple enzymatic defects in mitochondria in haematological cells of patients with primary sideroblastic anaemia. J Clin Invest 1980; 66: 43-49.
11. Gatterman N, Retzlaff S, Wang Y-L, Aul C, Schneider W. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxydase in two patients with acquired idiopathic sideroblastic anaemia. Blood 1997; 90: 4961-4972.
12. Bowen D. What is ineffective erythropoiesis in myelodysplastic syndromes? Leukemia Lymphoma 1995; 18: 243-247.
13. Rotig A, Bourgeron T, Chretien D, Rustin P, Munnich A. Spectrum of mitochondrial DNA rearrangements in the Pearson marrow-pancreas syndrome. Hum Mol Genet 1995; 4: 1327-1330.
14. Tuckfield A, Ratnaike S, Hussein S, Metz J. A novel form of hereditary sideroblastic anaemia with macrocytosis. Br H Haematol 1997; 97: 279-285.
15. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol 1995; 91: 612-617.
16. Appelbaum FR, Barall J, Storb R et al. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. ExpHematol 1990; 15: 1134-1139.
17. Yoshida Y, Oguma S, Uchino H, Maekawa T. Refractory myelodysplastic anemia with hypocellular bone marrow. J Clin Pathol 1988; 41: 763-767.
18. Tanawattanacharoen P, Molldrem J, Boccuni P et al. Glucosylphosphatidyl-inositol anchored protein deficient cells in myelodysplasia. Blood 1997; 90 (suppl 1): 202A.
19. Tichelli A, Gratwohl A, Wursh A, Nissen C, Speck B. Late haematological complications in severe aplastic anaemia. Br J Haematol 1988; 69: 413-418.
20. Ohara A, Kojima S, Hamajima N et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90: 1009-1013.
21. Yoshida Y, Stephenson J, Mufti GJ. Myelodysplastic syndromes: from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia. Int J Haematol 1993; 57: 87-97.
22. Bennett JM. FAB and MIC classification of myelodysplastic syndromes: points of controversy. In: Mufti GJ, Galton DAG. The myelodysplastic syndromes. Edinburgh: Churchill Livingstone 1992: 15-22.
23. May SJ, Smith SA, Jacobs A, Williams A, Bailey-Wood R. The myelodysplastic syndrome: analysis of laboratory characteristics in relation to the FAB classification. Br J Haematol 1985; 59: 311-319.
24. Antilla P, Ihalainen J, Salo A, Heiskanen M, Juvonen E, Palotie A. Idiopathic macrocytic anaemia in the aged: molecular and cytogenetic findings. Br J Haematol 1995; 90: 797-803.
25. De Witte T. New treatment approaches for myelodysplastic syndrome and secondary leukaemias. Ann Oncology 1994; 5: 401-408.
26. Appelbaum FR, Le Beau MM, Willman CL. Secondary leukemia. In: Hematology 1996. Education Program of the American Society of Hematology Annual Meeting 1996, pp 33-47.
27. Sanz GF, Sanz MA, Vallespi T et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395-408.
28. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
29. Seymour JF, Estey EH. The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes. Leuk Lymphoma 1995; 17: 79-85.
30. Brito-Babapulle F, Catovsky D, Gallon DAG. Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia. Br J Haematol 1987; 66: 445-450.
31. Galton DAG, Brito-Babapulle F. The relationship between acute myeloid leukaemia and myelodysplasia. In: Mufti GJ, Gallon DAG The myelodysplastic syndromes. Edinburgh: Churchill Livingstone 1992: 55-64.
32. Griesser GH, Horny HP. Hematopathological features of acute erythraemia (morbus Di Guglielmo). A contribution to the classification and differential diagnosis of erythroid neoplasias. Acta Hematol 1987; 77: 193-197.
33. Zittoun R. Chronic myelomonocytic leukaemia. In: Mufti GJ, Gallon DAG. The myelodysplastic syndromes. Edinburgh: Churchill Livingstone 1992: 65-88.
34. Groupe Francais de Cytogenetique Hematologique. Cytogenetics of chronic myelomonocytic leukemia. Cance Genet Cytogenet 1986; 21: 11-30.
35. Bennett JM, Catovsky D, Daniel MT et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Br J Haematol 1994; 87: 746-754.
36. Bartram C. Molecular genetic aspects of myelodysplastic syndromes. Hematol Oncol Clin North Am 1992; 6: 557-570.
37. Michaux JL, Martial P. Chronic myelomonocytic leukemia (CMML): a myelodysplastic or myeloproliferalive syndrome? Leukemia Lymphoma 1993; 9: 35-41.
38. Mufli GJ, Slevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplaslic syndromes: a scoring syslem with prognostic significance. Br J Haematol 1985; 59: 425-433.
39. Estey E, Keating M, Pierce S, Beran M. Application of the International Scoring System for Myelodysplasia to M.D. Anderson patients. Blood 1997; 90: 2843-2844 (letter).
40. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distincl haemalological disorder with deletion of ihe long arm of no. 5 chromosome. Nature 1974; 251 : 437-438.
41. Knudson AG. Anlioncogenes and human cancer. Proc Natl Acad Sci USA 1993; 90: 10914-10921.
42. Boullwood J, Lewis S, Wainscoal JS. The 5 q- syndrome. Blood 1994; 84: 3253-3260.
43. Le Beau MM, Espinosa R, Neuman WL et al. Cytogenetic and molecular delineation of the smallesl commonly deleled regon of chromosome 5 in malignant myeloid disorders. Proc Natl Acad Sci USA 1993; 90: 5484-5488.
44. Willman CL, Sever CE, Pallavicini MG et al. Deletion of IRF-1, mapping lo chromosome 5q 31.1, in human leukemia and preleukemic myelodysplasia. Science 1993; 259: 968-971.
45. Boultwood J, Fidler C, Lewis S el al. Allelic loss of IRF1 in myelodysplasia and acule myeloid leukemia: relenlion of IRF1 on the 5 q- chromosome in some palienls wilh Ihe 5 qsyndrome. Blood 1993; 82: 2611-2616.
46. Boultwood J, Fidler C. Chromosomal deletions in myelodysplasia. Leuk Lymphoma 1995; 17: 71-78.
47. Fearon ER, Vogelestein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
48. Miyake K, Inokuchi K, Nomura T. Expression of the DCC gene in human hematological malignancies. Leuk Lymphoma 1994; 16: 13-18.
49. Goasguen JE, Bennett JM. Classification and morphologic features of Ihe myelodysplaslc syndromes. Semin Oncol 1992; 19:4-13.
50. Niemeyer CM, Arico M, Basso G et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood 1997; 89: 3534-3543.
51. Luna-Fineman S, Shannon KM, Lange BJ. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood 1995; 85: 1985-1999.
52. Stiller CA, Chessels JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma. Br J Cancer 1994; 70: 969-972.
53. Shannon KM, O'Connel P, Martin GA et al. Loss of the normal NF1 allele from the bone marrow of children wth type 1 neurofibromatosis and malignant myeloid disorder. New Engl J Med 1994; 330: 597-601.
54. Parker J. Mufti GJ: Ras and myelodysplasia: lessons from the last decade. Semin Haematol 1996; 33: 206-224.
55. Side L, Taylor B, Cayouette M et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorder. New Engl J Med 1997; 336: 1713-1720.
56. Lai JL, Preudhomme C, Zandecki M et al. Myelodysplastic syndromes and acute myeloid leukemia with 17 p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 1995; 9: 370-381.
57. Sterkers Y, Preudhomme C, Lai JL et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocytaemia: relatively high incidence after hydroxyurea and high proportion of cases with 17 p deletion. Blood 1997; 90(suppl 1):348A.
58. Lambertenghi-Deliliers G et al. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol 1991; 78: 161-166.
59. Auerbach AD, Allen RG. Leukemia and preleukemia in Fanconi anemia patients. Cancer Genet Cytogenet 1991; 51: 1-12.
60. Buturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconi anemia: an international Fanconi anemia registry study. Blood 1994; 84: 1650-1655.
61. Sievers EL, Dale DC. Non-malignant neutropenia. Blood Rev 1996; 10: 95-100.
62. Bader-Meunier B, Mielot F, Tchernia G et al. Myelodysplastic syndromes in childhood: report of 49 patients from a French multicentre study. Br J Haematol 1996; 92: 344-350.
63. Groupe Francais de Cytogenetique Hematologique. Fortyfour cases of childhood myelodysplasia with cytogenetics, documented by GFCH. Leukemia 1997; 11: 1478-1485.
64. Gilchrist DM, Friedman JM, Rogers PCJ, Creighton SP. Myelodysplasia and leukemia syndrome wth monosomy 7: a genetic perspective. Am J Med Genet 1990; 35: 437-441.
65. Shannon KM, Turhan AG, Chang SS et al. Familial bone marrow monosomy 7. Evidence that the predisposing locus is not on the long arm of chromosome 7. J Clin Invest 1989; 84: 984-989.
66. Olopade O, Roulston D, Baker T et al. Familial myeloid leukemia associated with loss of the long arm of chromosome 5. Leukemia 1996; 10:669-674.
67. Marsden K, Challis D, Kimber R. Familial myelodysplastic syndrome with onset late in life. Am J Hematol 1995; 49: 153-156.
68. Mijovic A, Antunovic P, Pagliuca A, Mufti GJ. Familial myelodysplastic syndromes: a key to understanding leukaemogenesis? Leukemia Res 1997; 21 (suppl 1): 22a.
69. Cartwright RA, Glasan RW, Rogers HJ et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982; 2: 842-846.
70. Chen H, Sandler DP, Taylor JA et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta l (GSTT1) gene defect. Lancet 1996; 347: 295-296.
71. Preudhomme C, Nisse C, Hebbar M et al. Glutathione S transferase theta 1 gene defects in myelodysplastic syndromes and their correlation with karyotype and exposure to potential carcinogens. Leukemia 1997; 11: 1580-1582.
72. Mandla S, Goobie S, Kumar T et al. Analysis of cancer susceptibility genes in a family with myelodysplastic syndrome. Blood 1996; 88 (su'ppl 1): 207B.
73. Levine EG, Bloomfleld CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992; 19: 47-84.
74. Pui C-H, Relling MV, Rivera GK et al. Epipodophyllotoxinrelated acute myeloid leukemia: a study of 35 cases. Leukemia 1995; 9: 1990-1996.
75. Smith MA, McCaffrey RP, Karp JE. The secondary leukemias: challenges and research directions. J Natl Cancer Inst 1996; 88: 40718.
76. Tirman MJ, Larson RA. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 1996; 10: 293-320.
77. List AF, Spier CM, Cline A et al. Expression of the multiple drug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol 1991; 78: 28-34.
78. Pedersen-Bjergaard J, Rowley JD. The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780-2786.
79. Carter G, Hughes DC, Clark RE. Ras mutations in patients following cytotoxic therapy for lymphoma. Oncogene 1990; 5: 411-416.
80. Taylor C, McGlynn H, Carter G et al. Ras and Fms mutations following cytotoxic therapy for childhood acute lymphoblastic leukaemia. Leukemia 1995; 9: 466170.
81. Taylor C, Hughes DC, Zappone E et al. A screen for Ras mutations in individuals at risk of secondary leukaemia due to occupational exposure to petrochemicals. Leuk Res 1995; 19: 299-301.
82. Barbacid M. Ras oncogenes: their role in neoplasia. Eur J Clin Invest 1990; 20: 225-235.
83. Ben-Yehuda D, Krichevsky S, Caspi O et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996; 88: 4296-4303.
84. Felman P, Bryon PA, Gentilhomme O et al. The syndrome of abnormal chromatine clumping in leucocytes: a myelodysplastic disorder with proliferative features? Br J Haematol 1988: 70: 49-54.